title: Durable response after just one cycle of belotecan-based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma.
abstract: The efficacy of second-line chemotherapy for relapsed primary peritoneal serous carcinoma has been numerously reported, but reports on durable response after second-line therapy have been rare. We report the case of a 66-year-old woman with relapsed primary peritoneal serous carcinoma who showed durable response after just one cycle of second-line belotecan-based therapy. The response might be a complete pathologic remission. Considering the fact that our patient suffered from neutropenic sepsis during her treatment, we concluded that belotecan-based chemotherapy could be a good option for second-line chemotherapy in some selected patients, so patient selection should be carefully performed due to the toxicity of belotecan.
authors.affiliation: Department of Internal Medicine, Bucheon St Mary's Hospital, The Catholic University School of Medicine, Bucheon, Korea.
authors.forename: Guk Jin
authors.initials: GJ
authors.lastname: Lee
authors.forename: Ji Won
authors.initials: JW
authors.lastname: Min
authors.forename: Min Wu
authors.initials: MW
authors.lastname: Seo
authors.forename: Mi Yeong
authors.initials: MY
authors.lastname: Lee
authors.forename: Jong Youl
authors.initials: JY
authors.lastname: Jin
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D010537:Peritoneum / Q000187:drug effects*; D059004:Topoisomerase I Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D059004:Topoisomerase I Inhibitors; C116963:belotecan; D002945:Cisplatin; D002166:Camptothecin
keywords: belotecan; ovarian neoplasms; treatment efficacy